FLAGSTAFF, Ariz., Oct. 14, 2026 /PRNewswire/ — W. L. Gore & Associates’ medical business (Gore) today announced U.S. Food and Drug Administration approval of an expanded indication for the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis (VBX Stent Graft) for use in fenestrated and branched endovascular aortic repair (FEVAR and BEVAR).
“This FDA approval is an important milestone for physicians treating patients with complex aortic aneurysms,” said Jason Belzer, Gore Americas Business Leader. “We are proud to bring U.S. physicians an indicated bridging stent option for both FEVAR and BEVAR and to continue innovating to advance treatment options for patients with complex aortic disease.”